Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
A small single-centre study found that adding a long-acting GLP-1 receptor agonist to metformin lowered BMI but did not show a significant between-group glycaemic advantage. PICO summary and expert commentary.
Secondary analysis of the SELECT trial: semaglutide 2.4 mg increased regression to normoglycaemia and reduced progression to diabetes in adults with overweight or obesity and cardiovascular disease, yet did not slow glycaemic progression over time. PICO summary and expert commentary.
A secondary analysis of the SELECT trial examined whether weekly semaglutide 2.4 mg lowered all-cause, cardiovascular, non-cardiovascular, and COVID-19-related death in adults with overweight or obesity and cardiovascular disease without diabetes. PICO summary and expert commentary.
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showing semaglutide benefits were consistent across baseline inflammation strata. PICO summary and expert commentary.
Prespecified secondary analysis of the STEP-HFpEF Program testing whether semaglutide 2.4 mg benefits in obesity-related HFpEF differ by atrial fibrillation history. PICO summary and expert commentary.
A small double-blind randomized trial found once-daily oral semaglutide 50 mg lowered ad libitum energy intake and body weight versus placebo over 20 weeks, with no delayed gastric emptying. PICO summary and expert commentary.
STEP 10 randomised phase 3 trial of once-weekly semaglutide 2.4 mg versus placebo in adults with obesity and prediabetes: greater weight loss and reversion to normoglycaemia at 52 weeks. PICO summary and expert commentary.
Semaglutide 2.4 mg weekly was superior to placebo for physical functioning across the four 68-week STEP 1-4 trials. PICO summary and expert commentary.
A prespecified analysis of the SELECT trial reports semaglutide produced a mean weight reduction of 10.2 percent versus 1.5 percent for placebo, sustained over four years in adults with cardiovascular disease and obesity but without diabetes. PICO summary and expert commentary.
A prespecified secondary analysis of the STEP-HFpEF programme found that semaglutide 2.4 mg lowered NT-proBNP and produced larger health-status gains in patients with higher baseline NT-proBNP. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
